Evidence map›Paper›PMID 41331039›Full record

ArticleScientific reports2025

Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin.

Arkapravo Chattopadhyay, Mohammad Fatehi, Farag E S Mosa, Brittany Gruber, Peter E Light, Khaled Barakat

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Late IMedicinal research reviews · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arkapravo ChattopadhyayFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
Mohammad FatehiFaculty of Medicine and Dentistry, Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
Farag E S MosaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
Brittany GruberFaculty of Medicine and Dentistry, Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
Peter E LightFaculty of Medicine and Dentistry, Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
Khaled BarakatFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. kbarakat@ualberta.ca.

Funding

CIHR PJT-183967Natural Sciences and Engineering Research Council of Canada (NSERC) RGPIN-2020-04437
6 · The paper itself

Abstract

The cardiac voltage-gated sodium ion channel (Nav1.5) serves as a crucial regulator of cardiac excitability and presents a potential therapeutic target. While the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor dapagliflozin has exhibited cardioprotective effects, its structurally similar counterpart, ertugliflozin, which differs solely by an additional oxygen and methyl group, does not confer cardio-protection. To examine this discrepancy, a multiscale computational approach combining all-atom molecular dynamics (MD) and coarse-grained (CG) simulations was employed to analyze ligand interactions with Nav1.5 in both single and dual-binding site configurations. All-atom simulations revealed localized residue fluctuations but were inadequate for capturing system-wide allosteric effects. Consequently, CG models were derived from atomistic trajectories to improve conformational sampling. Critical residues regulating binding sites were identified through B-factor analyses in three replicas of all-atom models. Harmonic restraints were subsequently applied to these residues within the CG models to simulate ligand-induced rigidity. Notably, in the dual-binding configurations, ertugliflozin’s additional oxygen established a hydrogen bond interaction with Y1767, a mutation site associated with pathological late sodium current (late INa). This interaction was absent in single-site configurations and may elucidate the functional divergence between the two compounds. Furthermore, inter-residue distances between the IFMT motif, involving domains III and IV related to channel gating, were monitored to assess inactivation states across the various systems. This investigation underscores how dual-site occupancy and subtle chemical differences in ligands can impact Nav1.5 inactivation dynamics. The findings provide a foundation for structure-based design of selective modulators targeting sodium channels via allosteric mechanisms.

Indexed as

Benzhydryl CompoundsBridged Bicyclo Compounds, HeterocyclicGlucosidesNAV1.5 Voltage-Gated Sodium ChannelSodium-Glucose Transporter 2 InhibitorsAllosteric RegulationBinding SitesHumansLigandsMolecular Dynamics SimulationProtein BindingBenzhydryl CompoundsBridged Bicyclo Compounds, HeterocyclicdapagliflozinertugliflozinGlucosidesLigandsNAV1.5 Voltage-Gated Sodium ChannelSodium-Glucose Transporter 2 InhibitorsAllosteric modulationCardio-protectionDapagliflozinDual-site bindingErtugliflozinMultiscale modellingNav1.5Voltage-gated sodium channel

Identifiers

PMID41331039
PMCPMC12780251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.